KYNB Q2 2026 Earnings Call: $95.7M Liquidity and Q4 Clinical Catalysts
Source Tradingkey
Key Takeaways
- KYNB ended June 30, 2026 with $95.7 million in cash, cash equivalents, investments and accounts receivable. Management expects its cash runway to extend into 2028.
- The FG-3246 Phase 2 monotherapy trial in metastatic castration-resistant prostate cancer remains on track for an interim analysis of 36 patients in Q4 2026. The trial is expected to enroll 75 patients across three dose levels.
- Management is targeting median radiographic progression-free survival of at least 10 months for FG-3246, compared with 8.7 months in the earlier Phase 1 monotherapy trial.
- The company finalized the protocol for a Phase 3 roxadustat trial in lower-risk myelodysplastic syndromes and aims to initiate the study in Q4 2026, either internally with additional capital or through a strategic partnership.
- Q2 2026 operating costs and expenses increased to $16.1 million from $13.4 million a year earlier. The company recorded net income from continuing operations of $12.0 million, versus a $13.7 million net loss in Q2 2025.
Key Financial Data
| Metric | Q2 2026 | Q2 2025 | Commentary |
|---|---|---|---|
| Total revenue | -$1.5 million | $1.3 million | Revenue turned negative in the quarter |
| R&D expenses | $6.8 million | $5.9 million | Higher year over year |
| SG&A expenses | $9.3 million | $7.1 million | Higher year over year |
| Total operating costs and expenses | $16.1 million | $13.4 million | Increased by $2.7 million |
| Net income from continuing operations | $12.0 million | -$13.7 million | Compared with a net loss a year earlier |
| Basic and diluted EPS | $2.96 | -$3.38 | Per-share result from continuing operations |
| Cash, equivalents, investments and receivables | $95.7 million | — | As of June 30, 2026 |
Business and Operating Performance
FG-3246 and FG-3180 in metastatic prostate cancer
Disclaimer: For information purposes only. Past performance is not indicative of future results.
Recommended Articles
Financial Markets 2026: Volatility Catalysts in Gold, Silver, Oil, and Blue-Chip Stocks—A CFD Trader's OutlookGet a comprehensive financial market 2026 outlook exploring key economic drivers, volatility catalysts in gold, oil and stocks, and what the evolving economic outlook means for cfd trading strategies and risk management on global markets.
Get a comprehensive financial market 2026 outlook exploring key economic drivers, volatility catalysts in gold, oil and stocks, and what the evolving economic outlook means for cfd trading strategies and risk management on global markets.
As of the European session on August 11, gold prices (XAUUSD) briefly topped $4,400 intraday, reaching a high of $4,435.2, its highest level since June 5. However, gains subsequently narr
WTI declines below $82.50 as oil inventories rise far more than expectedWest Texas Intermediate (WTI), the US crude oil benchmark, is trading around $82.45 during the early Asian trading hours on Thursday. WTI declines on a larger-than-expected build in US crude oil inventories. Traders will closely monitor the developments surrounding US-Iran talks for fresh impetus.
West Texas Intermediate (WTI), the US crude oil benchmark, is trading around $82.45 during the early Asian trading hours on Thursday. WTI declines on a larger-than-expected build in US crude oil inventories. Traders will closely monitor the developments surrounding US-Iran talks for fresh impetus.
Here is what you need to know on Thursday, August 13:
WTI remains below $80.50 as traders monitor diplomatic efforts to reopen HormuzWest Texas Intermediate (WTI) oil price remains subdued for the third successive day, trading around $80.30 per barrel during the Asian hours on Friday. Crude oil prices edge lower as investors adopt a wait-and-see approach, closely monitoring diplomatic attempts to reopen the Strait of Hormuz.
West Texas Intermediate (WTI) oil price remains subdued for the third successive day, trading around $80.30 per barrel during the Asian hours on Friday. Crude oil prices edge lower as investors adopt a wait-and-see approach, closely monitoring diplomatic attempts to reopen the Strait of Hormuz.
